Your session is about to expire
← Back to Search
Corticosteroid
Otezla + Enstilar for Psoriasis
Phase 4
Waitlist Available
Led By L.H. Kircik, M.D.
Research Sponsored by Derm Research, PLLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4, week 16, week 20
Awards & highlights
Study Summary
This study is evaluating whether a combination of two medications may help treat psoriasis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 4, week 16, week 20
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4, week 16, week 20
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percent of subjects who are clear or almost clear on Physicians Global Assessment at Week 4
Secondary outcome measures
DLQI (dermatology life quality index) at week 4
DLQI at week 16
Itch VAS (visual analogue scale) at week 4 and week 16
+4 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Otezla + EnstilarExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apremilast
FDA approved
Find a Location
Who is running the clinical trial?
Derm Research, PLLCLead Sponsor
17 Previous Clinical Trials
542 Total Patients Enrolled
5 Trials studying Psoriasis
135 Patients Enrolled for Psoriasis
L.H. Kircik, M.D.Principal InvestigatorSkin Sciences, PLLC
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger